Stocks Health care ANAB
NASDAQ · Health careAnaptysbio, Inc (ANAB)
Anaptysbio, Inc brought in $232.4M of revenue over the twelve months to March 31, 2026, up 107.7% from a year earlier. It posted a net loss of $26.8M. Operating cash flow minus capital spending left $19.6M of free cash flow in fiscal 2025. At March 31, 2026 it held $248.5M in cash. Its latest periodic report to the SEC is the transition-period annual report (10-KT) filed on September 21, 2026.
What Anaptysbio, Inc does
Anaptysbio, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ANAB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $234.6M | -$13.2M | -$0.44 | $19.6M |
| 2024 | $91.3M | -$145.2M | -$4.92 | -$135.7M |
| 2023 | $17.2M | -$163.6M | -$6.08 | -$121.6M |
| 2022 | $10.3M | -$128.7M | -$4.57 | -$74M |
| 2021 | $63.2M | -$57.8M | -$2.11 | -$47.3M |
| 2020 | $75M | -$19.9M | -$0.73 | -$14.7M |
Latest SEC filings
What Anaptysbio, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 21, 2026Transition-period annual report 10-KT · period to June 30, 2026
- September 21, 2026Exhibits 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- July 30, 2026
- June 29, 2026
- June 29, 2026Additional proxy material DEFA14A
- June 29, 2026Proxy statement DEF 14A
- June 22, 2026
- May 29, 2026
Questions about ANAB
What does Anaptysbio, Inc do?
Anaptysbio, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ANAB.
Is Anaptysbio, Inc profitable?
No. Over the twelve months to March 31, 2026 it reported a net loss of $26.8M on revenue of $232.4M.
How much revenue does Anaptysbio, Inc make?
Over the twelve months to March 31, 2026 Anaptysbio, Inc reported revenue of $232.4M. That is 107.7% more than a year earlier.
When did Anaptysbio, Inc last report?
Its most recent periodic report is the transition-period annual report (10-KT) filed on September 21, 2026. It covers the period to June 30, 2026.
Similar companies
Follow ANAB
Get an email when Anaptysbio, Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow ANAB: get an email when it filesWhere the numbers come from
Financial figures are the values Anaptysbio, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.